Clinical Trials Management, LLC | Southshore, Metairie, LA logo

Clinical Trials Management, LLC | Southshore, Metairie, LA

Research site
Location
3801 Houma Boulevard, Suite 200, Metairie, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Budesonide
Vonoprazan
Buprenorphine
Fluconazole
Difamilast
SCY-078
Triglyceride
Lansoprazole
Ranolazine
Povorcitinib

Parent organization

This site is a part of Clinical Trials Management, LLC

Data sourced from clinicaltrials.gov

Active trials

10 of 65 total trials

A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults

The primary purpose of this study is to evaluate safety/ reactogenicity of INFLUENZA G1 mini-hemagglutinin stem-derived protein vaccine antigen (mHA)...

Active, not recruiting
Influenza Prevention
Biological: Al(OH)3
Biological: Placebo

This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD....

Active, not recruiting
Atopic Dermatitis
Drug: Difamilast

The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100...

Enrolling
Erosive Esophagitis
Drug: PPI Control
Drug: BLI5100

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Su...

Enrolling
Hidradenitis Suppurativa (HS)
Drug: Povorcitinib
Drug: Placebo

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurati...

Enrolling
Hidradenitis Suppurativa (HS)
Drug: Povorcitinib

The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women b...

Enrolling
Endometriosis
Drug: Placebo
Drug: OG-6219

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD)...

Enrolling
Change in Bone Mineral Density
Bone Loss
Drug: LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Enrolling
Eosinophilic Esophagitis
Drug: CC-93538

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling
Hyperuricemia
Tophi
Drug: Tigulixostat
Drug: Placebo

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Shire logo
B
Incyte logo
Ironwood Pharmaceuticals logo
Phathom Pharmaceuticals logo
AbbVie logo
Acrotech Biopharma logo
Amgen logo
Bausch Health logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems